SCROLL FOR IMPORTANT SAFETY INFORMATION, INDICATION, AND CO-PAY CARD TERMS & CONDITIONS

IMPORTANT SAFETY INFORMATION

LIPITOR® (atorvastatin calcium) tablets are
contraindicated in patients with a known
hypersensitivity to any component of this product;
in patients with active liver disease or unexplained
persistent elevations of hepatic transaminases; in
women who are or may become pregnant or who
are nursing.

Rare cases of rhabdomyolysis have been reported
with LIPITOR® (atorvastatin calcium) tablets
and other statins. Tell patients to promptly report
muscle pain, tenderness, or weakness.
Predisposing factors include advanced age (≥65),
uncontrolled hypothyroidism, and renal impairment.
Patients with a history of renal impairment merit
closer monitoring. In cases of myopathy or
rhabdomyolysis, therapy should be temporarily
withheld or discontinued.

The concomitant use of higher doses of LIPITOR®
(atorvastatin calcium) tablets with certain drugs
such as cyclosporine and strong CYP3A4 inhibitors
(eg, clarithromycin, itraconazole, and HIV protease
inhibitors) increases the risk of
myopathy/rhabdomyolysis. Lower doses of LIPITOR
should be considered. Physicians should carefully
monitor patients for signs or symptoms of
myopathy early during therapy and when titrating
the dose of either drug.

It is recommended that liver function tests be
performed prior to the initiation of therapy and
repeated as clinically indicated thereafter.

Increases in HbA1c and fasting serum glucose
levels have been reported with HMG-CoA
reductase inhibitors, including LIPITOR®
(atorvastatin calcium) tablets.

In a post hoc analysis of the SPARCL study in
patients without CHD who had a stroke or TIA
within the preceding 6 months, a higher incidence
of hemorrhagic stroke was seen in the LIPITOR®
80 mg (atorvastatin calcium) tablets group
compared with placebo (2.3% vs 1.4%). Some
baseline characteristics, including hemorrhagic
and lacunar stroke on study entry, were associated
with a higher incidence of hemorrhagic stroke in
the LIPITOR group.

The most commonly reported adverse reactions
with LIPITOR® (atorvastatin calcium) tablets in
placebo-controlled trials were: nasopharyngitis,
arthralgia, diarrhea, pain in extremity, and urinary
tract infection.

INDICATION

LIPITOR® (atorvastatin calcium) tablets are indicated
as an adjunct to diet to reduce the risk of myocardial
infarction (MI), stroke, revascularization procedures,
and angina in adult patients with multiple risk factors
but without clinically evident coronary heart disease
(CHD); to reduce the risk of MI and stroke in patients
with type 2 diabetes and without clinically evident
CHD, but with multiple risk factors; to reduce the risk
of nonfatal MI, fatal and nonfatal stroke,
revascularization procedures, hospitalization for
congestive heart failure, and angina in adult patients
with clinically evident CHD.

LIPITOR® (atorvastatin calcium) tablets, as an adjunct
to diet, are also indicated to reduce elevated total-C,
LDL-C, apo B, and TG levels; and to increase HDL-C
in patients with primary hypercholesterolemia
(heterozygous familial and nonfamilial) and mixed
dyslipidemia.

LIPITOR SAVINGS TERMS AND CONDITIONS

By using the LIPITOR Savings Card (the "Card"),
you attest that you meet the eligibility criteria and
will comply with the Terms and Conditions
described below:

You will pay $4 for a 30-day supply (30 tablets) if:
you use commercial/private insurance and your
out-of-pocket expense for a 30-day supply of
brand name LIPITOR is $130 or less.

You will pay $30 for a 30-day supply (30 tablets)
if:
you do not use prescription health coverage to
purchase your brand name LIPITOR under this
program or you use commercial/private insurance
and your out-of-pocket expense for a 30-day supply
of brand name LIPITOR is $130 or more. In addition:

a) Medicare Part D patients may participate in this
Card Program, but cannot use any part of their
Medicare Part D prescription benefit for LIPITOR
during the term of this offer.

b) Out-of-pocket expenditures under this Card
Program cannot be applied towards a patient’s
Medicare Part D true out of pocket (TrOOP)
expenses.

c) Patients participating in this category cannot
seek reimbursement for a purchase of LIPITOR
from any third party insurance entity during the
term of this offer.

This offer is not valid for prescriptions that are
eligible to be reimbursed, in whole or in part,
by Medicaid or other federal or state healthcare
programs (including any state prescription drug
assistance programs and the Government Health
Insurance Plan available in Puerto Rico [formerly
known as "La Reforma de Salud"]).

For all eligible patients, you can only qualify for
up to $2500 of savings per calendar year. After
a maximum of $2500, you will pay usual monthly
out-of-pocket costs.

This Card cannot be combined with any other
rebate/coupon, free trial, discount, prescription
savings card, or similar offer for the specified
prescription.

The Card will be accepted only at participating
pharmacies.

This Card is not health insurance.

Offer valid only in the U.S. and Puerto Rico, but not
for Massachusetts residents or where otherwise
prohibited by law.

The Card is limited to 1 use per person per
month during this offering period and is not
transferable. It is illegal to sell, purchase, trade,
or counterfeit, or offer to sell, purchase, trade, or
counterfeit this Card.

Pfizer reserves the right to rescind, revoke or amend
the Card Program without notice at any time.

You must be 18 or older to participate in this
Program.

Card Program expires December 31, 2018.

No membership fees.

For reimbursement when using mail order, mail copy
of original pharmacy receipt (cash register receipt
NOT valid) with product name, date and amount
circled to:

2250 Perimeter Park Drive
Suite 300
Morrisville, NC 27560

Be sure to include a copy of the front of Savings
Card, your name and mailing address.


This content is best viewed in landscape orientation.
Please re-orient your screen to view this page.